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Available online 3 February 2016The Genea019 human embryonic stem cell line was derived from a donated, fully commercially consented ART
blastocyst, through ICM outgrowth on inactivated feeders. The line showed pluripotent cell morphology and ge-
nomic analysis veriﬁed a 46, XXkaryotype, femaleAllele pattern and unaffectedHtt CAG repeat length, compared
to HD affected sibling Genea020. Pluripotency of Genea019 was demonstrated with 75% of cells expressing
Nanog, 89% Oct4, 48% Tra1-60 and 85% SSEA4, a Pluritest Pluripotency score of 22.97, Novelty score of 1.42, tri-
lineage teratoma formation and Alkaline Phosphatase activity. The cell line was negative for Mycoplasma and
any visible contamination.
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availableYES — GENEA020 (HD affected, XX — UKSCB: SCSC14-62)Materials and methods
Cell line derivation
The zona pellucida of a blastocyst-stage human embryo was re-
moved using pronase. The embryo was plated whole onto mitomycin
C inactivated human feeders (Detroit 551 HFF, plated 200,000 cells
per organ culture dish — 69,204 cells/cm2) in 20% Knock out serum in
standard hESC culture medium with 50 ng/mL Fgf2 (Amit et al., 2000).
CGH karyotyping and STR proﬁling was performed at the ﬁrst
cryobanking step from ICMoutgrowthsmaintained on feeders. Alkaline
Phosphatase staining was performed on feeders. Cells were then enzy-
matically passaged as single cells in M2 pluripotent cell maintenance
medium (Genea Biocells) and CGH/karyotyping repeated, immunoﬂuo-
rescent pluripotent marker staining, pluritest, teratoma and sterility
testing performed.nse (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
CGH analysis summary; Genea019 (passage 16, 4 enzymatic) reporting a female cell line
and no abnormalities detected.
CGH summary
Sample name Genea019 p16-TE4
Date reported 20th September 2012
Hybridisation balance Balanced hybridization was observed for all chromosomes,
relative to reference DNA
Copy number change No copy number changes above 400 kb were detected
Interpretation Female cell line — no abnormalities detected
Fig. 1.Morphology and karyotype of Genea019. A) Brightﬁeld (passage 55) growing on
human inactivated feeders. B) Alkaline phosphatase activity (passage 46) on human
inactivated feeders. C) Karyotypic analysis (passage 3) showing 46, XX normal, female
karyotype.
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1. Karyotyping: Passage 3; For enrichment of metaphase cells, cellular
outgrowths were incubated with either 0.22 ng/ml colcemid
(Invitrogen) and 37.5 g/ml BrdU (Sigma) for 17–19 h or 5 ng/ml
colcemid for 2.5 h. Single cells were subsequently obtained using
Non-Enzymatic Cell Dissociation Solution (Sigma) and transferred
to Sydney IVF's (now Genea) diagnostic cytogenetics laboratory
for preparation of metaphase spreads and cytogenetic analysis by
G-banding. A minimum of 15 metaphase cells were examined, of
which a full karyotype or chromosome counts was performed for 5
and 10 of the metaphases respectively.
2. Comparative Genomic Hybridisation (CGH) based chromosomal
analysis: Passage 16 (12 on feeders, 4 enzymatic); CGH was used to
screen targeted regions of the genome for gains and losses associated
with chromosomal imbalances such as aneuploidy, deletions and du-
plications. CGH was performed using SurePrint G3 microarrays
(8 × 60 K format) which were scanned with the Agilent Scanner C
and analyzed using Genomic Workbench Standard Edition 5.0 soft-
ware (Agilent Technologies).3. DNA Proﬁling: Passage 30; DNA ‘ﬁngerprinting’was performed using
the AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (Applied Biosystems
#4322288) to provide permanent genetic identiﬁcation of the
cell lines. https://www.thermoﬁsher.com/order/catalog/product/
4322288.
Pluripotency assessment
1. Alkaline Phosphatase: Passage 46; Genea019 grown on feeders were
stained as per manufacturers protocol using the Merck Millipore
Alkaline Phosphatase Detection Kit (SCR004).
2. Immunoﬂuorescence: Passage 16 (14 on feeders, 2 enzymatic); cells
were ﬁxed with formalin and stained with Nanog #560483 1:200;
Oct4 #560217 1:150: Tra1–60 #560,121 1:150; SSEA4 #560308
1:200 (all BD Pharmingen:). Images were acquired with an IN Cell
Analyzer 6000 and quantiﬁed using In Cell Developer Software (GE).
3. Pluritest: Passage 14 (12 on feeders, 2 enzymatic); RNAwas collected
and subjected to a Pluritest, a bioinformatic assay of pluripotency in
human cells based on gene expression proﬁles (Müller et al., 2012).
4. Teratoma formation: Passage 72; Stem cells were received one day
prior to injection. On the day of injection cells were harvested by
manual scraping, washed and resuspended in DMEM/20% KSR for
intramuscular injection of cells into the left inner thigh muscle of
the hind leg. Approximately 1–2 × 106 cells (1xT25) in 50 uL were
injected per mouse at one site only. Resultant teratomas were
excised, ﬁxed, sectioned and stained for assessment of tissues from
each of the embryonic germ layers.
Sterility testing
1. Mycoplasma: Passage 20; testing was performed at the Victorian
Infectious Diseases Reference Laboratory using Mycoplasma Genus
PCR.
2. Microbial contamination: testingwas performed in conjunctionwith
our QC measures. Cells were thawed and cultured in 7 mL antibiotic
free medium (Genea Biocells M2 medium) for 2–3 days at 37 °C. A
clear solution at ~48–72 h indicated lack of bacterial, fungal or
yeast contamination. Clarity of the solution was assessed by Cell
Production Team.
Veriﬁcation and authentication
Ethics/consents
Ethics approval for the project (‘the possibility that karyotyped em-
bryonic cells derived from non-viable “investigation” embryos could be
developed into stem cell lines’) was obtained from the Genea Ethics
Committee on 13 September 2005 under the Ethical Guidelines on the
Use of Assisted Reproductive Technology in Clinical Practice and Research
(ART guidelines, 2004) and the National Statement on Ethical Conduct
in Human Research. Karyotyped embryo cells were fully consented
for development of stem cells by all responsible people through an
informed consent process (signed de-identiﬁed consent form can be
provided upon request). Donors have received no payment of other
beneﬁts for their donation. Donated embryos originally created by
Table 2
STR proﬁle; Genea019 (passage 30) demonstrating female allele pattern.
D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S317 D16S539 D2S1338 D19S433 vWA TPOX D18S51 D5S818 FGA
SIVF19 12,13 29,30 7,8 10,11 15 9.3,10 11,12 11 18,23 13,14 17 11 12,18 11,12 22,23
399B. Dumevska et al. / Stem Cell Research 16 (2016) 397–400assisted reproduction technology (ART) for the purpose of procreation.
Embryos were identiﬁed as unsuitable for implantation, biopsy or
freezing due to abnormal development. Embryonic outgrowths were
developed for consented clinical investigation studies. Results of the
studies have been reported back to the patient.
PGD analysis conclusion
No mutation; 15 and 18 CAG repeats in HTT gene. No family tree;
embryo was de-identiﬁed. See (Bradley et al., 2011) for siblingship
and sequencing analysis.
Morphology
The derived stem cell line, Genea019, morphologically displays
adherent monolayer of compact cells in well-deﬁned colonies with
high nuclear to cytoplasmic ratio and prominent nucleoli (Fig. 1A/B).
Genetic analysis
The cell line has been karyotyped (Fig. 1C, Supplementary Fig. 1) and
also tested by CGH (Table 1, Supplementary Fig. 2), demonstrated 46,
XX karyotype, consistent with original derivation. Analysis of STR
markers showed Allele pattern consistent with female genotype
(Table 2, Supplementary Fig. 3).Fig. 2.Pluripotency validation ofGenea019. A) Immunoﬂuorescent staining (10×)of pluripoten
enzymatic). B) Quantitation of expression of pluripotent markers. C) PluriTest pluripotency (le
D) Tri-lineage teratoma formation (passage 72) with (left) bone, (middle) primitive mesenchyPluripotency
GENEA019 is pluripotent by;
1. Alkaline Phosphatase stain positivity (Fig. 1B).
2. Immunoﬂuorescence with 75% Nanog positive, 89% Oct4 positive,
48% Tra1-60 positive, and 85% SSEA4 positive (Fig. 2A, quantiﬁed in
2B).
3. Pluritest with a 22.97 Pluripotency score and 1.42 Novelty score
(Fig. 2C).
4. Teratoma formation which contained tissues derived from each of
the embryonic germ layers: endoderm, mesoderm, and ectoderm
(Fig. 2D).Sterility
The cell line is tested and found negative for Mycoplasma and any
visible contamination (Supplementary Fig. 4).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.02.008.
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